hematologic-malignancies
(2)
Solu Therapeutics
Solu Therapeutics is a Boston-based clinical-stage biotech building a new class of medicines that selectively kill disease-driving cells. Its proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms fuse the precise binding of small molecules with the cell-killing power of antibodies, reaching cell-surface targets - like GPCRs and ion channels - that traditional antibodies cannot. Its lead program, STX-0712, is a CCR2-targeting candidate in a Phase 1 trial for chronic myelomonocytic leukemia and other advanced blood cancers.
BlueSphere Bio
BlueSphere Bio is a Pittsburgh-based clinical-stage biotechnology company developing personalized T-cell receptor (TCR) therapies for cancer. Spun out of the University of Pittsburgh and UPMC Enterprises in 2017, the company's proprietary TCXpress platform rapidly discovers and screens natural T-cell receptors that can target cancer antigens hidden inside cells - a reach beyond what conventional CAR-T therapies achieve. Its lead programs target high-risk hematologic malignancies such as relapsed/refractory acute myeloid leukemia.